R&D News | pharmaphorum

News

Novo Nordisk forges close ties with biotech VC Flagship

Danish drugmaker Novo Nordisk has traditionally generated its pipeline mainly from internal R&D, but a new alliance with venture capital firm Flagship Pioneering signals another departu

News

AZ, Sanofi build case for one-shot RSV antibody

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respirat

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J ducks out of Bavarian Nordic vaccine partnerships

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis

News

Oxurion craters as failed trial cuts its pipeline down to on...

Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed a phase 2 trial and will be terminated.

News

Nykode vaccine shows its worth in cervical cancer trial

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.

News

Curebase bags $40m to develop patient-centric trials platfor...

Curebase has raised $40 million in second-round financing that will help it run more complex interventional trials for its biopharma clients, according to chief executive Tom Lemberg.

Novo Nordisk forges close ties with biotech VC Flagship

AZ, Sanofi build case for one-shot RSV antibody

J&J ducks out of Bavarian Nordic vaccine partnerships

Oxurion craters as failed trial cuts its pipeline down to on...

Nykode vaccine shows its worth in cervical cancer trial

Curebase bags $40m to develop patient-centric trials platfor...

Danco fights back after US court curbs abortion pill access

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks